Affordable Access

Access to the full text

Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis

Authors
  • Story, Kannika1
  • Sobel, Ryan1
  • 1 Thomas Jefferson University, Philadelphia, PA, USA , Philadelphia (United States)
Type
Published Article
Journal
Current Infectious Disease Reports
Publisher
Springer US
Publication Date
Jan 21, 2020
Volume
22
Issue
1
Identifiers
DOI: 10.1007/s11908-020-0712-7
Source
Springer Nature
Keywords
License
Yellow

Abstract

Due to broad spectrum susceptibility of Candida species to fluconazole, its convenience as an oral agent, and predictable patient tolerance and safety, current practice guidelines recommend the use of long-term suppression regimens of fluconazole as prophylaxis for recurrent vulvovaginal candidiasis (RVVC), as well as in abbreviated doses when known trigger factors emerge and inevitable symptomatic episodes are predictable. However, recent concerns of fluconazole-resistant Candida albicans strains may impact fluconazole use, particularly, concerns of overuse. This literature review discusses current recommendations for prophylaxis of vulvovaginal candidiasis with fluconazole.

Report this publication

Statistics

Seen <100 times